Abstract
BACKGROUND: Hyperthyroidism is the most common endocrinopathy in cats and is frequently managed using anti-thyroid medication.
HYPOTHESIS/OBJECTIVES: To develop and validate an algorithm to predict the optimal starting daily dose of thiamazole required to control hyperthyroidism in cats.
ANIMALS: One hundred eighty-eight client-owned cats with hyperthyroidism for algorithm development (2011-2021) and 45 hyperthyroid cats to validate the algorithm (2022-2024).
METHODS: Retrospective case-control study. Cats with hyperthyroidism controlled medically using thiamazole within a year since diagnosis were enrolled. Controlled dose of thiamazole was categorized into "≤5 mg" or ">5 mg." Binary logistic regression was performed to explore predictors associated with thiamazole dose. The performance of the final multivariable model in prediction was assessed by receiver operating characteristic (ROC) curve analysis. A cohort of cats subsequently diagnosed with hyperthyroidism and managed chronically with thiamazole were used to test algorithm performance.
RESULTS: At hyperthyroidism diagnosis, baseline plasma total thyroxine (TT4); (odds ratio [OR] 1.29 [95% CI, 1.19-1.42] per 10 nmol/L; P < .001) and creatinine concentrations (OR 0.83 [95% CI, 0.7-0.96] per 0.1 mg/dL; P = .02) were independent predictors for higher thiamazole dose (>5 mg). The area under the ROC curve was 0.92 (95% CI, 0.88-0.96). In the test cohort, 26 cats controlled on ≤ 5 mg and 19 required >5 mg thiamazole. The predictive model had overall accuracy of 91.1%, sensitivity of 84.2%, and specificity of 96.2%.
CONCLUSIONS AND CLINICAL IMPORTANCE: Hyperthyroid cats with higher plasma TT4 and lower creatinine concentrations at diagnosis are likely to require >5 mg total daily dose of thiamazole to achieve euthyroidism.